Nutex Health stock
NUTXNASDAQNutex Health, Inc., HealthcareISIN US67079U3068
74Score 74 out of 100, Strong
Price and trend
69 / 100
Price history
+41% in one yearThe chart shows daily closes over 14 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 35).
The price is 24% below its 52-week high. Largest decline in 14 years: 100% (December 2013 to July 2024).
Chart figures for advanced users
- SMA 50$202.78
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$151.89
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)35
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$87.01
- The lowest closing price of the last twelve months.
- Resistance$225.00
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Nutex Health, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $1.18B, is number 41 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $875.26M (up 82.4% year on year) and earnings of $70.79M (up 35.7%).
- For fiscal 2026, analysts expect on average revenue of $870.32M (down 0.6%) and adjusted earnings per share of $27.82 (up 209.8%).
Show more
- MEQIRI Score 74 out of 100 (Strong): rank 88 of 714 in Healthcare, median 53.
- The P/E is 7.3 (Medical (Care Facilities) median 19.4, own median of recent years 14.8).
- Our model puts fair value at $442.30, with the price 57% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 7.3, Medical (Care Facilities) median 19.4, own median 14.8.Valuation 91
- Growing faster than its industryRevenue up 26.1% a year since 2020, Medical (Care Facilities) median 9.2%.Growth 73
- High return on capitalReturn on invested capital 37.3% in fiscal 2025, Medical (Care Facilities) median 6.1%.Profitability 91
Weaknesses
- DilutionShare count up 48% since 2020.Capital allocation 54
- Volatile share priceVolatility 91% a year over the last 12 months.Stability 66
- Earnings per share fallingDown 14.7% a year since 2020.
Its standout strengths are profitability and valuation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $294.87 and expensive above $884.60 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $431.77 (cash-flow model) and $452.83 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $411.92, at 7.8% it would be $487.56.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 18.8% on the twelve months before. Revenue has grown strongly since 2017, at around 273% per year. From 2017 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 51%, operating 31%, net 8%. Last 12 months: net 21%. From 2017 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 4 Mar 2027in 112 days
- Last reported
- 5 Nov 2026EPS reported $5.71 (expected $5.54)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $27.82+0.1%
- Revenue
- $870.32M−0.2%
- Earnings per share
- $27.63−0.9%
- Revenue
- $960.29M−0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +30.0%No numerical guidance; three new facilities are expected to open in Q3 and Q4 2026, and revenue per visit is expected to remain similar.
“All 3 are expected to open in the third and fourth quarter of 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $43,493 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Saunders Scott JSale
18 Sept 2026, Board
- Shares
- 203
- Price
- $214.25
- Value
- $43,493
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Nutex Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 74
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- U.S. Physical TherapyUSPH $1.49B55
- AMN Healthcare ServicesAMN $1.47B65
- Aevis VictoriaAEVS.SW $1.45B34
- ClarianeCLARI.PA $1.37B39
- Innovage HoldingINNV $1.3B59
- Pennant GroupPNTG $1.29B54
- RHÖN-KLINIKUMRHK.DE $1.09B57
- Ramsay Générale de SantéGDS.PA $1.07B39
ETFs that hold Nutex Health
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.12% | 0.39% | €1.47B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.08% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.